Recruitment

Recruitment Status
Unknown status

Inclusion Criterias

Patient undergoing frozen embryo transfer
Patient undergoing frozen embryo transfer

Exclusion Criterias

Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
...
Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
Any contraindication to being pregnant and carrying a pregnancy to term.
Administration of any investigational drugs within three months prior to study enrollment.
Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
Body mass index (BMI) > 38 kg/m2
Irregular heart beat or already being treated with another medication for high blood pressure.

Summary

Conditions
Embryo Implantation
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Care Provider)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 45 years
Gender
Only females

Inclusion Criterias

Patient undergoing frozen embryo transfer
Patient undergoing frozen embryo transfer

Exclusion Criterias

Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
...
Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
Any contraindication to being pregnant and carrying a pregnancy to term.
Administration of any investigational drugs within three months prior to study enrollment.
Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
Body mass index (BMI) > 38 kg/m2
Irregular heart beat or already being treated with another medication for high blood pressure.

Locations

Jerusalem
Jerusalem

Tracking Information

NCT #
NCT02072291
Collaborators
Not Provided
Investigators
  • Principal Investigator: Assaf Ben-Meir, MD Hadassah Medical Center
  • Assaf Ben-Meir, MD Hadassah Medical Center